Phillip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 30,000 shares at $92.66 ($2.8M) on 2019-11-18, disclosed to the SEC on 2019-11-20.
Open-market sale of $2.8M ALNY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $91.17 | 5,559 | $507K | 18.4% |
| 2 | $91.17 | 5,559 | $507K | 18.4% |
| 3 | $91.97 | 8,631 | $794K | 28.9% |
| 4 | $91.97 | 8,631 | $794K | 28.9% |
| 5 | $92.66 | 810 | $75K | 2.7% |
| 6 | $92.66 | 810 |
| $75K |
| 2.7% |
| Total | $91.71 avg | 30,000 | $2.8M | 100% |
| Filing → |
| ALNY | SELL | 2022-08-17 | $12.8M | — | Filing → |
| ALNY | SELL | 2022-02-11 | $4.5M | — | Filing → |
| ALNY | SELL | 2020-11-30 | $7.5M | — | Filing → |